dual-targeting bispecific antibody alnuctamab in r/r multiple myeloma
Published 5 months ago • 84 plays • Length 2:44Download video MP4
Download video MP3
Similar videos
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
2:43
targeting multiple myeloma antigens
-
4:04
the future of myeloma treatment and the possibility of cure
-
6:17
myeloma made simple: bispecific antibodies made simple | bispecific antibodies for myeloma treatment
-
6:18
what to expect with car t cell therapy and bispecifics in myeloma (2022) | dr. joshua richter
-
1:48
the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
4:26
antibodies in multiple myeloma and their impact on treatment
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
1:53
infections following anti-bcma bispecific antibodies for multiple myeloma
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
2:53
novel targets and dual-targeting approaches in myeloma
-
4:27
antibody-based targeting of bcma in multiple myeloma
-
23:13
bispecific antibodies in multiple myeloma | dana-farber cancer institute
-
1:47
real-world outcomes of tandem transplantation in patients with newly diagnosed multiple myeloma
-
2:48
novel targets in multiple myeloma